• Citer

Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.

par Neymark, Niels;Gorlia, Thierry;Adriaenssen, Ines;Baron, Benoît;Piccart-Gebhart, Martine
Référence PharmacoEconomics, 20, 7, page (485-497)
Publication Publié, 2002

Article révisé par les pairs

• Détails
• Contenu

Titre:	Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.
Auteur:	Neymark, Niels; Gorlia, Thierry; Adriaenssen, Ines; Baron, Benoît; Piccart-Gebhart, Martine
Informations sur la publication:	PharmacoEconomics, 20, 7, page (485-497)
Statut de publication:	Publié, 2002
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Antineoplastic Combined Chemotherapy Protocols -- economics
	Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
	Cisplatin -- administration & dosage
	Cost-Benefit Analysis
	Cyclophosphamide -- administration & dosage
	Female
	Health Care Costs
	Humans
	Ovarian Neoplasms -- drug therapy
	Ovarian Neoplasms -- mortality
	Paclitaxel -- administration & dosage
Note générale:	Clinical Trial
	Comparative Study
	Journal Article
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:1170-7690
	info:doi/10.2165/00019053-200220070-00006
	info:pii/200706
	info:scp/0036071038
	info:pmid/12093304